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Introduction
During the transformation process tumor cells often
change their phenotype, what leads to tumor escape
from the immune system. Downregulation of the MHC
class I antigens is one of the possible strategies of this
escape. The mechanisms responsible for that phenom-
enon include, i.e. β2-microglobulin gene mutations,
changes in binding of transcription factors and MHC
class I mRNA gene expression, allele or haplotype loss
caused i.e. by a mutation encoding for heavy chain of
MHC molecule [1]. However, many other irregulari-
ties in a production and functioning of proteins respon-
sible for intracellular peptide transport may appear.
These changes can influence functions of proteasome
proteins (i.e. LMP2, LMP7), as well as transport pro-
teins (TAP 1 and/or TAP2), or chaperone proteins (i.e.
tapasin) [2]. Before proteasome processed protein will
be loaded on MHC molecules it has to be relocated
from the cytoplasm into the lumen of endoplasmic
reticulum (ER). TAPs belong to an ABC protein fami-
ly [3]. TAP proteins complex is responsible for the
transport of MHC molecules into ER.
Cells with a defect in TAP complex function are not
able to present properly an antigen. As a consequence
of TAP proteins absence or dysfunction, MHC mole-
cules can be held inside the ER lumen, or empty MHC
class I may be presented on a cell surface. Such empty
MHC class I molecules have a decreased lifetime.
Generally, they are stopped in the ER as only the
whole MHC complex consisting of a MHC heavy
chain,  2-microglobulin and a bound peptide can be
efficiently presented on the cell sufrace [4]. The lack
or decreased protein and/or gene expression of MHC
class I and the TAP was previously observed in many
cancer cells, i.e. in the small-cell lung carcinoma [5],
colorectal tumor [6], primary cervical carcinoma [7],
malignant melanoma [8], renal cell carcinoma [9],
squamous cell carcinomas of the head and neck
(SCCHN) [10], primary breast carcinomas [11], pri-
mary ovarian carcinoma [12], as well as in many
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established cancer cell lines i.e. in the cell lines of the
neuroblastoma [13], sarcoma [14], pancreas, biliary
tract and colon cancer [15], prostate cancer [16],
small-cell lung carcinoma [17]. 
Based on these studies we decided to assess the
expression of MHC class I molecules and a molecular
analysis of TAP genes expression in selected human
cancer cell lines. We tested the cell lines from cancers
in which a downregulation of MHC class I, TAP1 and
TAP2 was obserwed previously by other authors.
Materials and methods
Cell lines and culture conditions. Studied material consisted of
twenty human malignant tumor cell lines (Table 1). All cell lines
were obtained from prof. Andrzej Mackiewicz from the Depart-
ment of Cancer Immunology, University School of Medical
Sciences at Great Poland Cancer Center (Poznañ, Poland). Cell
lines was cultured in standard humidity and temperature condi-
tions in RPMI-1640 medium conditioned with 10% fetal calf
serum (FCS), with 2 mM L-glutamine and 1% penicillin and
streptomycin (100 μg/ml). 
Immunohistochemistry. Presence of surface antigens on the cells
was estimated by Alkaline Phosphatase-Anti-Alkaline Phosphatase
(APAAP) reaction [18]. Aceton fixed pellets were incubated at 4°C
per night with an unconjugated primary monoclonal mouse antibody
(anti-human HLA-ABC, clone W6/32, DAKO A/S). After removal of
unbound antibodies cell pellets were incubated at room temperature
by 30 minutes with the rabbit antibody anti-mouse immunoglobulins
(DAKO). After second wash the specimens were incubated for 30
minutes with APAAP complex (DAKO). Two last steps were
repeated for complete binding of free epitopes in order to increase
sensitivity of the reaction. Preformed complexes were visualized
by the incubation with substrate, consisted of alkaline fuchsin
(New Fuchsin), naphthol (Naphthol ASBI phosphate) and lev-
amisol (all from Sigma). After staining by Meyer's hematoxylin
and mounting in glycerogel the specimens were assessed under
light microscope.
Semi-quantitative assessment of immunohistochemical stained
specimens was performed in the case of positive reaction. The ratio
was established between the number of positive cells and whole
cell number in one microscopic field. The intensity of reaction was
referred in scores to the four degree scale of reactivity (Appendix
for Table 2).
Quantitative image analysis. Microscopic images were recorded by
digital camera (Color View) integrated with light microscope (Olym-
pus BX41). Using analySIS^B software the image analysis system
was calibrated for the chosen objective (10×), brightness, contrast and
color saturation of the microscopic image. Setting parameters were
applied for all recorded images from the same specimen. Digital
images were recorded at the 2560×1920 resolution. In the next step
images were converted to the 640×480 resolution and saved in TIF
format. The images prepared in this manner were subjected to the
computer morphometric analysis with the spatial visualization. Mor-
phometric survey of the HLA class I molecules was performed by
"A4D" software [19]. Using this software the surface area of positive
reaction was plotted (S) by pixel counting. Obtained results were
referred as percentage contribution of the color reaction in the micro-
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Table 1. Established tumor cell lines used.
scopic visual field. Values were obtained from the ratio between sur-
face area of reaction (S) and image resolution (R):
Flow cytometry. Expression of MHC class I molecules was
assessed by direct immunofluorescence. Antibodies anti-HLA-
ABC (clone W6/32, DAKO A/S) used in reaction were conjugated
with phycoerythrin (PE). Intracellular staining was performed by
the addition of 0.1% the saponine to cell suspension. Data acquisi-
tion and analyses were performed by FACScan with the CellQuest
(Becton Dickinson) software. Percentage of positive cells estimat-
ed quantity of cells presenting analyzed protein. RFI value indicat-
ed quantity of analyzed proteins. Protein values were considered
positive when at least 5% cells showed its expression. The relative
fluorescence intensity (RFI) were obtained by evaluation of mean
fluorescence intensity (MFI) of analyzed samples and appropriate
isotypic controls.
MFI - mean fluorescence intensity of an examined sample
MFIC - mean fluorescence intensity of an isotype control
RNA extraction. Total cellular RNA was isolated using RNeasy®
Mini Kit (50) (Qiagen) from the cell pellets, according to the man-
ufacturer's instruction. Nucleic acid concentration was measured
by spectrophotometr (Perkin-Elmer) at λ=260 nm. For quality esti-
mation isolated RNA was subjected to the electrophoresis on the
1.5% agarose gel with ethidium bromide (0.5 μg/ml).
Reverse transcription reaction (RT). Samples of total RNA were
used for RT reaction. Templates (0.5 μg/μl) were incubated at 65°C
and quickly cooled on ice. To the single RNA sample reaction solu-
tion was added that contained dNTPs, MgCl2, ribonuclease inhibitor
(RNaseOut , Invitrogen), oligo dT and MuLV reverse transcriptase
(Invitrogen). The mixture was incubated at 42°C, and then denaturat-
ed at 99°C. 3-glycerophosphate aldehyde dehydrogenase gene
(GAPDH) was used as a marker gene for constitutive expression.
Amplification with primers: F: 5'-GGTCGGAGTCAACGGATTTG-3'
and R: 5'-ATGAGCCCCAGCCTTCTCCAT-3' [20] was per-
formed for 30 cycles with AllegroTag DNA Polymerase
(Novazym). PCR products (386 bp) were subjected to elec-
trophoresis on 2% agarose gel.
Polymerase chain reaction (PCR). TAP1 and TAP2 mRNA expres-
sion was assessed by PCR with AllegroTag DNA Polymerase
(Novazym). Primers sequences used for PCR reactions were
designed using Primer3, Omiga and BLAST software. Primers
sequences for TAP1: F: 5'-TGGTCTGTTGACTCCCTTACAC-3'
and R: 5'-AAATACCTGTGGCTCTTGTCC-3' [NCBI GenBank
NM_000593], and TAP2: F: 5'-TACAACACCCGCCATCAG-3'
and R: 5'-AGGTCTCTCCGCCAATACAG-3' [NCBI GenBank
NM_018833]. Annealing temperature optimization was achieved
by temperature gradient PCR (56°C TAP1 and 61°C TAP2). Reac-
tion products (301 bp TAP1 and 185bp TAP2) were tested by elec-
trophoresis on 2% agarose gel.
Real-time PCR. Quantitative real-time PCR analysis was per-
formed by LightCycler (Roche Diagnostics). Reaction mixture
consisted of QuantiTect SYBR Green PCR Master Mix (Qia-
gen). After "hot-start" denaturation at 95°C samples were run by
45 cycles reaction with annealing at appropriate temperatures for
each gene. To obtain melting curve which defined specificity of
the amplification, samples were submitted for 15 second to
denaturation at 95°C, cooled at 65°C and re-warmed at 95°C.
Finally they were cooled at 40°C to complete product synthesis.
Data analysis was performed by Light Cycler Software v3.5
(Roche).
Standard curve. Standard curves were drawn for defining the
number of analyzed genes copies to total RNA ratio. Results of
each analyzed sample were referred to reference values from the
standard curve. To obtain standard curve 50 μl PCR products of the
each studied genes were submitted to electrophoresis on 2%
agarose gel. After electrophoresis and quality control on transilu-
minator, appropriate products were cut from gel. Products were
eluted from the gel by GenEluteTM Agarose Spin Column (Sigma)
using the manufacturer's protocol. Concentration of the purified
products was measured by spectrophotometer. Obtained values
were calculated according to the formula:
In the next step samples were water diluted in appropriate dilu-
tion series: 104, 103, 102, 10, 1, 10-1, 10-2, 10-3, 10-4 (aM) and added
to real-time PCR reactions for indication of the reference values.
Standard curves were prepared separately for each of the studied
gene and used for calculation of the initial amounts of the cDNA
in the analyzed samples. To confirm specificity of the reaction one
sample without the cDNA (negative control) were also amplified in
each of the analyzed sample set. Lack of the signal in the negative
control confirmed specificity of the reaction.
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Table 2. Expression of HLA-ABC on the studied cell lines.
Results of semi-quantitative and quantitative immunohistochemi-
cal studies.
Appendix. Semi quantitative four degree scale of reactivity.
Statistical analysis. Nonparametric Spearman rank correlation
tests and nonparametric U Mann-Whitney tests were carried out
using Excel (Microsoft) and Statistica (StatSoft) software. All
cytometric data were measured in duplicate and are presented in
the table as mean.
Results
Assessment of expression of MHC class I 
molecules
Immunohistochemical analysis showed expression of
the HLA class I molecule on the cells all tested cell
lines (Fig. 1A). Results of the semi-quantitative
assessment of specimens and quantitative image
analysis are shown in detail in the Table 2. There was
no correlation between semi-quantitative assessment
and digital image analysis except for A549 and HT29
cell lines. The highest values of the latter (<14%) in
A549 and HT29 cell lines corresponded to +++ scores
of the former. In other cases such parallel results were
usually not found.
Flow cytometry studies have shown that most of
the cell lines studied were able to stabily express of
MHC class I molecule both on the cell membrane as
well as in the cytoplasm (Fig. 1B). Detailed data has
been shown in the Table 3. In the most of studied
cases the surface expression of the MHC molecule
was higher than its intracellular expression. Almost
all cells of renal cancer cell line p54 have shown cell
membrane HLA molecule expression, but in cells of
other renal cancer p66 this expression was minimal.
The percentage of positive cells expressed in cyto-
plasm was highest in the cells of breast cancer MDA-
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Fig. 1. A. The expression of HLA-ABC antigen on the human lung cancer (A549 cell line). Immunohistochemistry, APAAP reaction.
Negative control and positive reaction. B. Surface and cytoplasmic expression of HLA-ABC antigen analyzed by flow cytometry. Per-
centage of positive cells and relative fluorescent intensity (RFI) obtained in the A375 and WM239 melanoma cell lines.
MB 231 and in those of thyroid cancer TT, but low-
est in HT29 cells. In addition, relative fluorescence
intensity (RFI) value evaluating the expression level
of the examined protein, its intracellular and surface
quantity, had the highest HLA class I molecule
expression on the cells of p66 line, both in the cyto-
plasm and on the cell surface. The lowest value of the
RFI was detected in the cytoplasm of colon cancer
HT29 cells and on the cell surface of WM239
melanoma cells (Table 3).
In the statistical analysis the Spearman rank test
showed correlations between percentage of positive
cells expressed HLA-ABC intracellular and on the cell
surface, the correlation coefficient was 0.5121 at the
p<0.05 (Fig. 2A) and between RFI of HLA-ABC
measured intracellular and on the cell surface, the cor-
relation coefficient was 0.5851 at the p<0.05 (Fig. 2B)
for all tested cell lines. The Percentage of positive cells
and RFI of HLA-ABC was not dependent on the type
of malignancy (epithelial origin or malignant mela-
noma) and on the source of its malignant origin (pri-
mary origin or metastasis).
Molecular analysis of TAP1 and TAP2 genes
expression
In molecular terms the RT-PCR revealed the presence
of mRNA transcripts for TAP1 (Fig. 3A) and TAP2
(Fig. 3B) genes in all human malignant tumor cell
lines examined.
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Table 3. Expression of HLA-ABC on the studied cell lines. Results of flow cytometry analyzes. Data shown the percentage of positive
cells and the Relative Fluorescence Intensity (RFI) measured on the surface and in the cytoplasm of tested cells.
Quantitative evaluation of the expression of both
TAP genes by real-time PCR was performed in five
selected cell lines: p66, HepG2, A375, WM9 and
WM239. Based on the standard curve the amounts of
transripts were estimated. The obtained values were
used to calculate the number of gene copies within the
total RNA isolated from the cells. Results indicate
lower level of both TAP1 and TAP2 genes expression
in comparison with GAPDH used as a housekeeping
gene. Within the total RNA isolated from the tested
cell lines the number of GAPDH gene copies were one
log higher than those encoding for the both subunits of
TAP heterodimer (105:104). Moreover, TAP2 gene
expression was lower than that of TAP1 (Fig. 4A).
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Fig. 2. Correlation between percentage of positive cells expressed HLA-ABC intracellular and on the cell surface  - Spearman rank test
(A). Correlation between RFI of HLA-ABC intracellular and on the cell surface - Spearman rank test (B).
Fig. 3. Expression of the genes coding TAP1 (A) and TAP2 (B) proteins. Electrophoretic analysis of RT PCR. cDNA from analyzed cell
lines, line M: mass marker, GeneRulerTM 100 bp DNA Ladder (Fermentas), line - cDNA: no cDNA, negative control PCR. Products size
of the PCR products: TAP1 301 bp., TAP2 185 bp.
Table 4. Quantitative real-time PCR for TAP1 and TAP2 gene
expression level in tested cancer cell lines. Data are shown as ratio
between the number of gene copies of TAP1 and TAP2 in  g of total
RNA to copies of GAPDH in  g of total RNA for duplicate assays.
Based on the data obtained, the expression poten-
tial of studied cells could be estimated (gene expres-
sion level). This value represents a ratio between the
number of gene copies of TAP1 or TAP2 in μg of
total RNA and copies of GAPDH in μg of total RNA.
Calculated expression potential showed differences
between analysed genes in cell lines studied (Table 4).
The highest ratio was found for TAP1 gene in cells
of malignant melanoma WM9. The lowest number
was observed in the cells of other melanoma cell line
A375. Similar to TAP1 gene expression the highest
expression of TAP2 genes was observed in cells of
melanoma WM9, and the lowest in cells of A375
(Fig. 4B).
A nonparametric U Mann-Whitney's test showed
statistically significant differences (p<0.05) in the
gene expression between the control gene GAPDH
and the TAP1 and TAP2 genes in the cell lines tested.
The significant difference at the p value <0.05 was also
found between the TAP1 and TAP2 genes expression
in the cell lines examined (Fig. 5A). Spearman corre-
lation test has shown trend suggesting the number of
gene TAP1 copies proportional to RFI of MHC class I
molecules of the studied cells (Fig. 5B).
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Fig. 4. Copy number of the studied genes to the total RNA (μg) isolated from cultured cells ratio (A). The TAP1 and TAP2 genes expression
level - a ratio between the number of gene copies of TAP1 or TAP2 in μg of total RNA and copies of GAPDH in μg of total RNA (B). 
Fig. 5. The significant statistical difference between the TAP1 and TAP2 genes expression (lines indicated mean values) - nonparametric
U Mann-Whitney's test (A). Correlation between the number of gene TAP1 copies and RFI of MHC class I molecules on the cell surface
of the studied cells - Spearman rank test (B).
Discussion
The key component of sufficient antigen binding and
presentation by major histocompatibility complex are
the interactions between the TAP protein complex
and MHC class I molecules [21]. Several previous
studies have shown that one of the main strategies of
cancer's escape from immune system control is par-
tial or total loss of its ability to synthesize proteins
taking part in antigens processing, transport and pres-
entation [13,22-28]. In this study we demonstrated
the expression of HLA class I molecule in all cell
lines tested. We also revealed in these cell lines the
presence of mRNA coding TAP1 and TAP2 proteins
on molecular level. Our results are in line with the
studies of the other authors who indicated previously
the presence of MHC class I molecules and/or TAP
proteins in the HepG2 [29], HCT116 [30], MCF-7,
MDA-MB231 and A549 [31], HT29 [31,32] cell
lines. 
Immunohistochemical analysis performed in our
study localized expression of the HLA class I molecule
both on the surface and intracellularly in all tested cell
lines. Semi-quantitative methods based on score range
are subjective and dependent on researchers experi-
ence. Digital imaging analysis was used therefore for
the assessment of specimens in objective and repro-
ducible manner [33]. The possibility of visualization
of the proteins presented in the cell membrane with
their simultaneous quantitative analysis increase the
information about topography and amount of analyzed
molecule. Standardization should refer to preparation
and staining of tissue, size of specimen, number of
photographed fields, microscopy resolution and lens
enlargement [34]. Lack of correlation between results
of cytometric and morphometric analyzes in the per-
formed studies may suggest insufficient stability of
some above-mentioned conditions.
Tumor's capability to present its antigens in concert
with MHC class I molecules on the cell surface is sub-
stantial to create specific adaptive response of cytotox-
ic T cells (CTL) [35]. Flow cytometry revealed pres-
ence of MHC molecules both on the surface and in the
cytoplasm of tested cells. Relative fluorescence inten-
sity of MHC class I molecules was higher in the cell
membrane than that in the cytoplasm. This finding
may be explained by fast migration of antigen present-
ing complex to the cell surface which remain for long
time in cell membrane.
Our molecular studies have shown the ability of all
cell lines tested synthesize mRNA molecules for both
TAP1 and TAP2 subunits. Clinical symptoms of TAP
protein deficiency include chronic inflammation of the
respiratory tract and granulomatous skin lesions [36].
Lack of transcripts encoding TAP subunits were previ-
ously reported in some of the cancer cell lines [9,37].
However, the presence of TAP transcripts does not
always substantiate the synthesis of functional TAP
protein heterodimer.
In our study, expression of TAP1 and TAP2 mRNA
was detected in the hepatocellular carcinoma cell line
Hep3B, which shows permanent hepatitis B virus pres-
ence. Proper functioning of TAP heterodimer can be
diminished by various agents like viral proteins which
may inhibit TAP heterodimer activity [38-41]. We
could deduce that TAPs mRNA synthesis in Hep3B
cells is not inhibited by virus. This observation corre-
spond with results of Chen et al. [42] and Wang et al.
[43] in which they demonstrated that HBV can induce
the expression of HLA class I molecule and TAP1 in
other hapatocellular carcer cell line HepG2.
In further steps, we performed quantitative assess-
ment of expression levels of both TAP genes using
real- time PCR for collecting information on the num-
ber of mRNA copies in comparison to total RNA iso-
lated from tumor cells. Based on this, we could pre-
cisely define expression level of genes of interest in
selected tumor cell lines tested. High expression of
both TAP subunits in WM9 cell line corresponds to the
presence of TAP transcripts in primary melanoma cor-
related with tumors regression [8]. Low levels of TAP
genes expression in A375 and WM239 melanomas are
in line with decrease or lack of expression of one or
both TAP genes in malignant melanomas [28].
Decrease in the expression of TAP1 and TAP2 genes in
melanoma WM239 cell line may correspond with pre-
viously established functional deficiencies of cells
with melanoma origin [22]. In renal cancer cell line
p66 number of TAP1 gene copies was fairly high in
comparison to the number of gene copies in A375 and
WM239 melanoma cell lines. TAP2 gene expression
level was not significantly different in the above men-
tioned cell lines. Moreover, we showed the presence of
TAP transcripts in kidney tumor cell lines though pre-
vious findings of the lack of expression of this genes in
renal cancers [44]. Presence of TAP1 and TAP2
mRNA in HepG2 corresponded to the literature data
[29]. Nonstimulated cancer cell lines had much lower
expression of TAP genes level in comparison with the
GAPDH gene. We found some correlation in the
expression potential between TAP2 and GAPDH
genes in some of the cell lines tested. No such correla-
tion could be found for TAP1 gene expression. In gen-
erally, our results indicated that TAP1 gene expression
level was higher than TAP2, unlike than Imanishi et al.
[15] who showed that ratio of copy numbers of mRNA
for TAP1 and TAP2 genes to GAPDH housekeeping
gene was higher for TAP2 than TAP1 in tested pan-
creas, biliary tract and colon cancer cell lines. Our data
rather confirm observations of Dissemond et al. [8]
who showed higher TAP1 protein expression in com-
parison to TAP2 in the cells from primary melanoma
lesions. This may suggest a dominant role of TAP1
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gene expression in formed TAP heterodimer and may
indicate that TAP1 protein stabilizes TAP2 protein,
and both subunits are regulated in parallel. Because of
TAP1 is an constitutively expressed gene and its
expression may be regulated by signal transducer and
activator of transcription 1 alpha (STAT1) and inter-
feron regulatory factor 1 (IRF1) [45] observed dis-
crepancies in its expression between different types of
cancers may occur because of different cancer
microenvironment.
Advances in the recent understanding of tumor
immunology have revealed several different mecha-
nisms by which tumors have escaped immune sur-
veillance. Such mechanisms include the weak expres-
sion of MHC class I molecules of cancer cells [46].
Several immunotherapeutic strategies for antigen
transporting protein deficiency comprise transfer of
genes encoding for distinct subunits in order to
reconstitute TAP proteins [47,48]. Other approach is
transfer of the genes coding the INF  and TNF  into
the cells expresing low expression level of TAPs for
their upregulation [44]. Another suppose is downreg-
ulation of the TAPs expression by IL-10 for increase
of the cancer cells sensitivity to NK cells action [49].
The established cell lines are the model of the exper-
imental environment so that the results of our study
may be helpful to further exploration of the antigen
processing and presentation machinery function in
vitro conditions. Precise examination of mechanisms
involved in processing, transport and antigen presen-
tation on MHC class I molecules by tumor cells leads
to further understanding of tumors biology and may
in future show the way to more effective tumor ther-
apies. 
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